Filing Flows › Elite Pharmaceuticals (ELTP) › Q3 FY25
Elite Pharmaceuticals (ELTP) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Feb 13, 2025
Elite Pharmaceuticals (ELTP) reported revenue of $14.4M for the third quarter fiscal 2025 (Q3 FY25), -8% from a year earlier and -24% from the quarter before. Operating margin was 7.6%, net loss $10.9M (75.8% of revenue).
Elite Pharmaceuticals, Q3 FY25: revenue $14.4M (-8% year over year), operating margin 7.6%, net loss $10.9M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.4M | -24% | -8% |
| Operating profit | $1.1M | — | — |
| Net earnings | −$10.9M | — | — |
| Operating cash flow | −$1.1M | — | — |
What changed
Revenue was $14.4M in Q3 FY25, down 8% year over year and down 24% from the previous quarter. Manufacturing was the largest line at 96% of revenue. Manufacturing lost $1.1M year over year (down 7%), 90% of the total change.
Gross margin was 42.6%, down 2.7 points from a year earlier. Operating profit was $1.1M, a 7.6% margin (down 15.1 points year over year). Operating expenses grew 43% against a revenue fall of 8%. The fastest-growing cost line was General & admin (+59%). The quarter ended with a net loss of $10.9M, narrower than the previous quarter's $11.0M loss. Net interest and other expense of $11.8M was the main reason.
Operating cash flow was −$1.1M. Non-cash charges added back $313K of depreciation and $71K of share-based compensation. Working capital and other items added $9.4M.
Questions
What was Elite Pharmaceuticals' revenue in the third quarter fiscal 2025?
Elite Pharmaceuticals (ELTP) reported revenue of $14.4M for the third quarter fiscal 2025 (Q3 FY25), -8% from a year earlier and -24% from the quarter before.
Was Elite Pharmaceuticals profitable in the third quarter fiscal 2025?
Operating profit was $1.1M (7.6% of revenue) and net loss $10.9M.